Trial Profile
A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Bipolar depression; Breast cancer
- Focus Biomarker; Therapeutic Use
- 29 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Jun 2016 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
- 24 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.